Bantam Pharmaceutical Presents New Preclinical Data for BTM-3566 at the American Association for Cancer Research (AACR) Annual Meeting 2025
• BTM-3566 shows solid tumor regression and identifies FAM210B as a potential biomarker for response and combination strategies

